{"id":5089,"date":"2021-02-24T18:08:43","date_gmt":"2021-02-25T02:08:43","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5089"},"modified":"2021-02-24T18:08:43","modified_gmt":"2021-02-25T02:08:43","slug":"effect-of-a-genetically-engineered-interferon-alpha-versus-traditional-interferon-alpha-in-the-treatment-of-moderate-to-severe-covid-19-a-randomised-clinical-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/24\/effect-of-a-genetically-engineered-interferon-alpha-versus-traditional-interferon-alpha-in-the-treatment-of-moderate-to-severe-covid-19-a-randomised-clinical-trial\/","title":{"rendered":"Effect of a Genetically Engineered Interferon-Alpha versus Traditional Interferon-Alpha in the Treatment of Moderate-to-Severe COVID-19: A Randomised Clinical Trial"},"content":{"rendered":"<p>A randomized clinical trial comparing the effectiveness of a modified \u201csuper-compound interferon\u201d (rSIFN-co) to standard of care in China (which includes treatment with traditional interferon-alpha) indicated that rSIFN-co was associated with a shorter time to clinical improvement. Patients were blinded to treatment arm and received the standard of care, which also included lopinavir-ritonavir or umifenovir but the treating clinicians were aware of study assignment. Only 10% of participants received corticosteroids. Clinical improvement was defined as two-points improvement on the WHO scale. In this cohort, the time to clinical improvement in the rSIFN-co group compared to interferon-alpha was 11.5\u2009days versus 14.0\u2009days, the overall rate of clinical improvement on day 28 was 93.5% versus 77.1%, and the time to virus nucleic acid negative conversion was 7.0\u2009days versus 10.0\u2009days. Adverse events were balanced with no deaths among either group.<\/p>\n<p><i>Li et al. (Jan 1, 2021). Effect of a Genetically Engineered Interferon-Alpha versus Traditional Interferon-Alpha in the Treatment of Moderate-to-Severe COVID-19: A Randomised Clinical Trial. Annals of Medicine. <\/i><a href=\"https:\/\/doi.org\/10.1080\/07853890.2021.1890329\">https:\/\/doi.org\/10.1080\/07853890.2021.1890329<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A randomized clinical trial comparing the effectiveness of a modified \u201csuper-compound interferon\u201d (rSIFN-co) to standard of care in China (which includes treatment with traditional interferon-alpha) indicated that rSIFN-co was associated with a shorter time to clinical improvement. Patients were blinded to treatment arm and received the standard of care, which also included lopinavir-ritonavir or umifenovir&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/24\/effect-of-a-genetically-engineered-interferon-alpha-versus-traditional-interferon-alpha-in-the-treatment-of-moderate-to-severe-covid-19-a-randomised-clinical-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-5089","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5089"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5089\/revisions"}],"predecessor-version":[{"id":5090,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5089\/revisions\/5090"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5089"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}